

# Recombinant CTLA-4 Extracellular Domain $\square$ Fc fragment (human IgG1 isotype) Protein

Catalog No.: YR0046

## Basic Information

### Molecular Weight

### Endotoxin

<1EU/mg (<0.001EU/ $\mu$ g) Determined by LAL gel clotting assay

### Sterility

0.2  $\mu$ m filtration

### Aggregation

<5% Determined by SECP

### Purity

>95% Determined by SDS-PAGE

## Background

Belatacept (trade name Nulojix, Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Belatacept differs from abatacept (trade name Orencia) by only 2 amino acids. The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation.

## Reported Applications

Functional assays, and those assays for studying biological pathways affected by belatacept.

## Immunogen Information

### Clone

Belatacept Biosimilar

### Isotype

Human IgG1 Fc

### Immunogen

/

### Recommended Isotype Control(s)

In Vivo Grade Recombinant Human IgG1 Fc Protein

### Recommended Dilution Buffer

1×PBS pH 7.2 to 7.8

## Contact

	400-999-6126
	<a href="mailto:cn.market@abclonal.com.cn">cn.market@abclonal.com.cn</a>
	<a href="http://www.abclonal.com.cn">www.abclonal.com.cn</a>

## Product Information

### Production

Purified from cell culture supernatant in an animal-free facility

### Purification

Protein A or G purification

### Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)